GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Cyclically Adjusted Revenue per Share

Enzo Biochem (Enzo Biochem) Cyclically Adjusted Revenue per Share : $2.08 (As of Jan. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enzo Biochem's adjusted revenue per share for the three months ended in Jan. 2024 was $0.169. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.08 for the trailing ten years ended in Jan. 2024.

During the past 12 months, Enzo Biochem's average Cyclically Adjusted Revenue Growth Rate was -9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enzo Biochem was 7.30% per year. The lowest was -3.20% per year. And the median was 3.50% per year.

As of today (2024-06-08), Enzo Biochem's current stock price is $1.13. Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $2.08. Enzo Biochem's Cyclically Adjusted PS Ratio of today is 0.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzo Biochem was 4.64. The lowest was 0.48. And the median was 1.32.


Enzo Biochem Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Enzo Biochem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cyclically Adjusted Revenue per Share Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.52 2.40 2.45 2.39 2.18

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.29 2.28 2.18 2.13 2.08

Competitive Comparison of Enzo Biochem's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Enzo Biochem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cyclically Adjusted PS Ratio falls into.



Enzo Biochem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enzo Biochem's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0.169/130.1244*130.1244
=0.169

Current CPI (Jan. 2024) = 130.1244.

Enzo Biochem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.554 100.023 0.721
201407 0.565 100.520 0.731
201410 0.557 100.176 0.724
201501 0.513 98.604 0.677
201504 0.524 99.824 0.683
201507 0.558 100.691 0.721
201510 0.545 100.346 0.707
201601 0.528 99.957 0.687
201604 0.572 100.947 0.737
201607 0.565 101.524 0.724
201610 0.568 101.988 0.725
201701 0.567 102.456 0.720
201704 0.584 103.167 0.737
201707 0.548 103.278 0.690
201710 0.573 104.070 0.716
201801 0.557 104.578 0.693
201804 0.536 105.708 0.660
201807 0.482 106.324 0.590
201810 0.451 106.695 0.550
201901 0.409 106.200 0.501
201904 0.413 107.818 0.498
201907 0.438 108.250 0.527
201910 0.425 108.577 0.509
202001 0.408 108.841 0.488
202004 0.354 108.173 0.426
202007 0.409 109.318 0.487
202010 0.598 109.861 0.708
202101 0.655 110.364 0.772
202104 0.672 112.673 0.776
202107 0.510 115.183 0.576
202110 0.547 116.696 0.610
202201 0.702 118.619 0.770
202204 0.538 121.978 0.574
202207 -1.111 125.002 -1.157
202210 0.146 125.734 0.151
202301 0.154 126.223 0.159
202304 0.326 127.992 0.331
202307 -0.395 128.974 -0.399
202310 0.156 129.810 0.156
202401 0.169 130.124 0.169

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Enzo Biochem  (NYSE:ENZ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enzo Biochem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.13/2.08
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzo Biochem was 4.64. The lowest was 0.48. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enzo Biochem Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203